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Abstract 
Malaria is a potentially lethal disease caused by species of the plasmodium parasite. 
Despite the advances in the interventions for its control and approaches to manage its 
fatality, morbidity and mortality rates are still high. At present, artemisinin-based 
combination therapy is the first line of treatment. However, there is the need to explore 
newer approaches as reduced effectiveness and multi-drug resistance (even to 
artemisinin) has been reported in some regions and is expected to widen in scope. 
Phytomedicines have shown promise for the management of this debilitating disease 
and there are abundant resources in most of the areas where this disease is endemic. 
This report would systematically review the literature, emphasizing the challenges 
encountered in the control of malaria, active phytochemicals currently utilised in the 
management, drug delivery approaches as well as the nanotechnology-based 
systems that could be exploited in its treatment. These phytomedicines, either 
delivered conventionally or via the use of advanced delivery systems may suggest 
new strategies towards the better management of malaria. 
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Abbreviations: 
ACT, artemisinin-based combination therapy; AUC, area under the plasma 
concentration-time curve; CNT, carbon nanotubes; HPMA, N-(2-hydroxypropyl) 
methacrylamide copolymer; IC50, 50% inhibitory concentration; ITM, improved 
traditional medicines; LLIN, long lasting insecticidal nets; LUV, large unilamellar 
vesicles; MLV, multilamellar vesicles; MWCNT, multi-walled carbon nanotubes; NLC, 
nanostructured lipid carriers; PAMAM, polyamidoamine; PEG, polyethylene glycol; 
PLA, poly lactic acid; PLGA, poly (lactic-co-glycolic acid); PGA, polyglutamic acid; PPI, 
polypropyleneimine; RBC, red blood cells; SLN, solid lipid nanoparticles; SMEDDS, 
self microemulsifying drug delivery systems; SWCNT, single-walled carbon 
nanotubes; Tmax, time to peak concentration; TPGS, d-α-Tocopheryl polyethylene 
glycol 1000 succinate 
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1. INTRODUCTION 
1.1 THE DISEASE ‘MALARIA’ 
Malaria is a debilitating disease, widespread in many tropical and subtropical regions. 
WHO ascribed over half a million deaths to the disease in 2013. In humans, this lethal 
mosquito-borne disease is caused by the plasmodium species; Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae and Plasmodium ovale with 
Plasmodium falciparum responsible for the most fatalites.  Despite its current high 
mortality, it has been demonstrated that global health initiatives continue to make 
progress in reducing its cases and deaths. 
Increased resistance to currently used antimalarial therapies signifies an urgent need 
to discover and develop novel drugs alongside more effective drug delivery systems. 
Plants are widely used as a first line remedy for the infection in malaria-endemic areas, 
with reports of up to 80 % of the local population in some developing countries 
dependent on these as their primary source of healthcare [1]. Willcox and Bodeker [2] 
prepared a database with 1277 plant species from 160 families being used to treat 
malaria or fever. With the resurgence in the interest and use of plant medicines as well 
as more plants being discovered for malaria treatment, this figure is presently thought 
to be higher. However, despite their popular use, an important drawback of these 
phytomedicines is their need for proper standardisation and assurance of quality, 
safety and efficacy. 
Although WHO recommends artemisinin-based combination therapy (ACT) as the 
drugs of choice for uncomplicated malaria, some current conventional 
pharmaceuticals used to manage this debilitating disease are known to have low 
bioavailability and adverse side effects. This is in addition to limitations and 
complications presented by increased resistance to conventional therapy by the 
parasites and multiple dosage regimens that reduce patient adherence etc. This is 
coupled with the narrow therapeutic index of some of the drugs, posing potential for 
toxicity when administered in the traditional form. Primaquine recommended in 
combination with ACTs to reduce transmissibility of vivax malaria could cause 
haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase deficiency. 
Chloroquine used for treating uncomplicated knowlesi, malariae, ovale or vivax 
plasmodium infection, while quinine and clindamycin recommended for certain special 
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risk groups have been reported to cause adverse effects including dizziness, skin 
rashes, sleep disturbances, agranulocytosis, risks of cardiac, neurological toxicity and 
neuropsychiatric reactions among others [3-5]. Looking at these limitations there arise 
a definite need for viable alternatives to current antimalarial therapy.  
Delivering drugs on the nanoscale confers numerous potential advantages which 
researches are exploiting. These include increased efficacy, lower doses and less 
incidences of side effects. This is obtained through controlling the distribution of the 
drug through passive and active targeting to specific sites. Also, nanoengineering of 
these particles can ensure the formulation of effective carriers that may improve 
bioavailability and biocompatibility [3, 4].  
With the global wave in nanotechnology in numerous applications, malaria treatment 
has not been left out. Research through different mechanisms on nanotechnologies 
for malaria treatment is on-going. Nanotechnology is being used in controlling the 
mosquito vector as well as killing the malaria parasite, as alternatives to conventional 
methods. For instance, the use of silver nanoparticles is gaining wide interest against 
mosquito-borne diseases. A study demonstrated the potency of a novel technique 
combining synthesize silver nanoparticles and the aqueous leaf extract of Bauhinia 
variegata, which resulted in a cheap, safe and environmentally friendly product [5]. A 
recent study developed nano-imitations (using polymer vesicles) of host cell 
membranes which was successful in deceiving and tricking malaria pathogens, thus 
proving useful as a potential approach towards developing novel vaccine strategies 
against malaria [6, 7].  In the study, it was revealed that these simple nanostructures 
could prevent invasion into host cells, thereby effectively interrupting the life cycle of 
the malaria pathogen. 
Researchers are increasingly exploring the application of nanotechnology based 
systems to herbal actives for various therapeutic application. The main focus of this 
article is providing an evidence for exploring nanotechnologies for the effective therapy 
of malaria utilising phytomedicines. A review of the literature reporting plant-based 
medicines, their use and potential as nanotechnology systems was conducted on 
research databases. Relevant studies were identified through searches of online 
databases (including PubMed, Cochrane database, Google Scholar and Web of 
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Science). Evidence to support the use and potential of nanophytomedicines for 
malaria is gaining significant interest and is reviewed here. 
2. CURRENT PHYTOMEDICAL MANAGEMENT OF MALARIA 
Antimalarial drug use and vector control are the most common approaches towards 
malaria control. Malaria, being an ancient disease, it is believed that early man might 
have resorted to the use of plant medicines in its management. Numerous locales are 
presently known to still wholly or partially rely on herbal medicines and the 
phytochemicals therein to abate symptoms and provide cure for the disease. They are 
suggested to be safer, have less adverse effect profiles, easier accessibility without 
the need for prescriptions and have better tolerability. Several plants have been 
reported as being effective and are used in the treatment of malaria. Current 
antimalarials derived from plants include artemisinin, and quinine. There are reports 
on the use of Anarcadium occidentalis (Anacardiaceae), Azadirachta indica 
(Meliaceae), Artemisia annua (Asteraceae), Cassia alata (Caesalpinioideae), 
Cinchona spp (Rubiaceae), Cochlospermum planchonii (Cochlospermaceae), Lippia 
multiflora (verbenacea), Khaya anthotheca (Meliaceae), Cryptolepis sanguinolenta 
(Apocynaceae), Myrtus communis (Myrtaceae), Phyllanthus amarus 
(Euphorbiaceae), Satureja thymbra (Lamiaceae), Thymus herba-barona (Lamiaceae) 
[8-10]. A main limitation of these plant-based medicines is the lack of/insufficient 
standardisation. Despite this, the evidence-based use of some of these 
phytomedicines in treating and managing malaria is widely reported [2, 8]. 
2.1 ACTIVE PHYTOCHEMICALS IDENTIFIED FOR MALARIA THERAPY 
Several phytochemicals have been identified for their relevance in malaria therapy. A 
summary of this is illustrated in Table 1.  
2.1.1 Alkaloids 
Although generally bitter tasting, they are commonly used as phytomedicines and a 
plant may have different alkaloids. The highest concentrations of alkaloids are usually 
found in leaves, roots and barks. The root extract of Cryptolepis sanguinolentan 
containing the bioactive indoquinoline alkaloids is currently under clinical development 
for malaria treatment and is widely used in several African countries. These alkaloids 
have shown both in vitro and in vivo activity against Plasmodium falciparum including 
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chloroquine-resistant strains [11, 12]. For instance, its herbal tea formulation has 
shown good clinical efficacy and safety in patients who had clinical features of 
uncomplicated malaria [12]. Another study examined the clinical efficacy of orally 
administered root decoction of Cochlospermum planchonii in comparison with 
chloroquine in the treatment of non-severe malaria [13]. Following treatment for five 
days, the study reported that 57% of chloroquine-treated and 52% of herbal-treated 
patients were cured, showing no detectable parasitemia, while at least 90% of all 
patients were asymptomatic. It has been reported that not only the alkaloids were 
active, but also saponins, tannins, phenolics, steroids, anthraquinones, which were 
present in the root decoction [14]. 
2.1.2 Essential oils 
Volatile, aromatic essential oils obtained from plants have proven to be useful in the 
control of malaria [15, 16]. They are environmentally friendly and are composed of 
bioactive compounds, hence their preference as suitable alternative mosquito larval 
control agents, and are potentially suitable for use in integrated pest management 
programs due to their safety and efficacy profile [17]. Dell’Agli et al investigated the 
anti-plasmodial effect of some plants used in the environmental control of the mosquito 
vectors of malaria. Myrtus communis, Satureja thymbra and Thymus herba-
barona were examined following extraction of the essential oils using distillation 
techniques and chromatographic fractionation. The active components identified in 
these herbs included thymol, acylphloroglucinols (including myrtucommulone), which 
potently reduced parasitaemia in mice infected with P. berghei, with the essential oil 
of S. thymbra being the most active against P. falciparum [9].   
2.1.3 Polyphenols 
They are generally categorised into stilbenes, flavonoids, lignans and phenolic acids, 
based on the phenolic rings and the hydroxyl substitutions between these (Figure 1a).  
Numerous polyphenols have been reported to be active in the fight against malaria, 
including those obtained from Euphorbia hirta, Annona senegalensis, Steganotaenia 
araliacea, Zanthoxylum fagara, Khaya senegalensis, Phyllanthus muellerianus, Ficus 
exasperate, Hoslundia opposita, Xanthium brasilicum and Pupalia lappacea [18-20]. 
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2.1.3.1 Flavonoids 
Flavonoids (Figure 1b-e) are believed to exert these beneficial effects through their 
characteristic modulation of cell signalling pathways and antioxidant effects. Several 
flavonoids have been identified as being the bioactive moiety from phytomedicines 
used in combating malaria [21]. Artemisia annua and Artemisia indica from which the 
WHO recommended first line artemisinin-based combination therapy emanates is a 
classic example of a phytomedicine with the flavonoid responsible for its bioactivity 
[22, 23]. Some of the flavonoids identified in  Artemisia include; artemetin, 
quercimeritrin, chrysosplenol C, retusin, chrysosplenol D, eupatin, 
chrysosplenetine,  apigenin, luteolin, acacetin, chrysoeriol and chrysin [23]. Clinical 
studies have proven that artemisinin and its derivatives are effective when used in 
malaria caused by P. vivax and P. falciparum, including uncomplicated and cerebral 
malaria [24-26].  
2.1.3.2 Tannins 
The antimalarial properties of tannins (Figure 1a) are widely reported. For instance, 
Punica granatum fruit rind are used as a traditional herb in malaria therapy, however, 
the fraction enriched in tannins showed greater activity against P. falciparum [27]. In 
a study, ellagitannins obtained from the fruit rind of Punica granatum 
(pomegranate) have shown potent antimalarial activity, in comparison to other 
phytochemicals obtained through an inhibition of the pro-inflammatory mechanisms 
involved in the onset of cerebral malaria [9, 28, 29]. Studies have revealed the 
antiplasmodial effect of several bioactives (including tannins) from Chromolaena 
odorata [30], Holoptelea integrifolia [31], Waltheria indica [32] and Horsfieldia 
spicata [33]. 
2.1.3.3 Lignans 
There are reports on lignans Figure 1g) being exploited as lead compounds in new 
drug development, including antimalarial drug development [34, 35]. de Andrade-Neto 
et al reported the antiplasmodial effect of Aryltetralone Lignans extracted 
from Holostylis reniformis, where it was shown that these extracts were effective 
against Plasmodium berghei and a chloroquine-resistant strain of Plasmodium 
falciparum [36]. Another study reported that the tetrahydrofuran lignan- calopeptin 
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from Nectandra megapotamica had shown in vitro antimalarial activity against 
Plasmodium falciparum [37]. Lignans isolated from Vernonia amygdalina, Pycnanthus 
angolensis, Hypericum lanceolatum, Glossocalyx brevipes, Asparagus africanus and 
Morus mesozygia have been reported to have antiplasmodial activity [21, 38, 39]. 
2.1.3.4 Stilbenes 
Despite their benefits of antioxidative, anticarcinogenic and antiinflammatory 
properties, many stilbenes (Figure 1h) have been reported to possess antimalarial 
activity. For instance, a stilbene glycoside isolated from Parthenocissus tricuspidata 
has shown significant blood schizontocidal activity when tested in vivo against P. 
berghei, with mean survival time similar to that for chloroquine [40]. Mishra et al. have 
reported the inhibitory effect of piceatannol on protein tyrosine kinase at different 
growth stages of P. falciparum. Here it was shown that significant inhibition was 
observed in trophozoites and schizonts which may be due to the relevant role of 
protein tyrosine kinase in the initial asexual maturation of the plasmodium parasite 
[41].  Sharma et al. went further to show the antiplasmodial activity of novel stilbene-
chalcone hybrids, where the potency of some hybrids against chloroquine sensitive 
and resistant strains of P. falciparum were reported through different mechanisms 
including chromatin condensation, blocking the progression of the parasite life cycle 
at the ring or the trophozoite stages, DNA fragmentation and loss of parasitic 
mitochondrial membrane potential. This could be due to these hybrids causing 
apoptosis in malaria parasite [42]. 
2.1.4 Glycosides 
Some glycosides (Figure 1 i-m) have shown some in vitro and in vivo antimalarial 
efficacy. For instance, flavonol glycosides obtained from the extracts of Hydrangeae 
macrophylla and Euphorbia hirta (afzelin, quercitrin and myricitrin) showed P. 
falciparum inhibition at significantly low concentrations, without any signs of 
cytotoxicity [43, 44]. The study also assessed the anti-malarial activity of other flavonol 
glycosides including, rutin, multinoside, isoquercitrin and quercitrin flavonols, which 
showed some antimalarial activity though not as potent as that from extracts of 
Hydrangeae macrophylla [43]. Cucurbitacin glycosides obtained from the traditional 
commonly used plant Datisca glomerata (including datiscoside and datiscoside B), 
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have shown moderate in vitro antiplasmodial activity when the isolated compounds 
were compared against a chloroquine sensitive strain of P. falciparum [45]. 
2.1.5 Terpenes and terpenoids 
Certain terpenes and terpenoids (Figure 1n) have been identified as being useful in 
malaria therapy. Some are being used as mosquito repellents, while others are 
parasiticidal.  Rodrigues et al investigated some terpenes/terpenoids (farnesol, 
limonene, linalool and nerolidol) using cultures of the intraerythrocytic stages of the 
falciparum parasite. The study concluded that linalool, farnesol and nerolidol exhibited 
stronger inhibitory activity on the biosynthesis of the isoprenic side chain of the 
benzoquinone ring of ubiquinones in the schizont stage and combining these terpenes 
with other antimalarial drugs could be an approach to be exploited for malaria therapy 
[46]. Artemisinin, the first line antimalarial treatment base (derived from Artemisia 
annua) is a potent terpene believed to aid its malarial therapeutic response [47].  
Table 1: Phytochemicals reported for their antimalarial effect 
Phytochemical Plants for 
malaria 
Family Specific 
phytochemicals 
Plant part 
extracted 
Pharmacokinetic and safety data Reference 
Alkaloids 
Cinchona spp. Rubiaceae Modified 
monoterpene-
derived alkaloids 
(e.g. quinine, 
quinidine, 
cinchonidine, 
cinchonine) 
Bark  Cinchona alkaloids have shown significant 
cardiovascular effects and are administered 
by rate-controlled infusions, due to the 
potential of result of lethal hypotension.  
Quinine monotherapy is the most widely 
used treatment for malaria during the first 
trimester of pregnancy. It is thought to  be 
safe in all trimesters of pregnancy 
[48-50] 
Aspidosperma 
spp (including  
Aspidosperma 
olivaceum) 
Apocynaceae Monoterpenoid 
indole alkaloids 
(MIAs); 
aspidoscarpine, 
uleine, apparicine, 
and N-methyl-
tetrahydrolivacine 
Aspidospermine 
Olivacine  
 
Bark 
Leaves 
Extract fractions showed in vitro activity in at 
low doses (IC50 < 5.0 μg/mL) using the anti-
HRPII test. Two fractions were toxic to 
HepG2 cells 
[51] 
Cryptolepis 
sanguinolenta 
Apocynaceae Indoquinoline 
alkaloids 
Roots An orally administered water extract of 
Cryptolepis sanguinolenta has shown 
efficacy comparable to chloroquine in a 
clinical study. Using animal toxicity testing 
data (from mice, rats and rabbits), its herbal 
formulation appears safe 
[11, 12] 
Cochlospermum  
spp. (including 
Cochlospermum 
planchonii and  
Cochlospermaceae 
 
Roots 
 [13] 
The crude extract of Cochlospermum 
tinctorium showed potent antiplasmodial 
activity in mice, though fractions 
demonstrated lower activity 
[52] 
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Cochlospermum 
tinctorium)  
Anthraquinones Pentas 
micrantha 
 
Rubiaceae 5,6-dihydroxylucidin-
11-O-methyl ether 
Roots Moderate antiplasmodial activity against 
certain Plasmodium falciparum strains as 
well as low cytotoxicity in MCF-7 cells 
[53] 
Flavonoids Artemisia annua 
 
Artemisia indica 
 
Artemisia 
absinthium  
 
Artemisia dubia 
Asteraceae  Exiguaflavone A, 
Exiguaflavone B, 
Maackiain, 
2-(2, 4-
dihydroxyphenyl)-
5,6-methylene 
dioxybenzofuran 
Eupatin, Casticin, 
Chrysoplenetin, 
Cirsilineol, 
Chrysophenol-D, 
Artemetin  
Leaves 
Flowers 
Roots 
Stem 
Extracts and the volatile oil of Artemisia 
indica demonstrated activity against malaria 
parasites, malaria prophylactic effect 
(through inhibition of recombinant plasmodial 
fatty acid biosynthesis (PfFAS-II) enzymes. 
They also showed low cytotoxicity against 
mammalian cells 
 
 
[54-56] 
Glycosides Stachytarpheta 
cayennensis 
 
 
Hydrangea 
macrophylla 
Verbenaceae 
 
 
 
Hydrangeaceae 
Phenylethanoid 
glycosides 
 
 
Flavonol glycosides 
Leaves 
 
 
 
Leaves  
Glycosidic extracts demonstrated significant 
blood schizonticidal activity in Albino Swiss 
mice which was comparable to that of the 
standard drug, chloroquine 
There was significant proliferation inhibition 
of Plasmodium falciparum at significantly low 
concentrations with the absence of 
cytotoxicity 
[57, 58] 
 
 
 
[43] 
Polyphenols Sebastiania 
chamaelea 
 
Chrozophora 
senegalensis 
 
Anogeissus 
leiocarpus 
 
 
Euphorbiaceae 
 
 
Euphorbiaceae 
 
 
Combretaceae 
 
 
 
Ellagic acid 
 
 
Ellagic acid 
 
 
Ellagic acid 
Gallic acid 
Gentisic acid 
 
Leaves  
Stem 
Bark 
Studies have shown that 
S. chamaelea extracts have no significant 
cytotoxicity, significant antiplasmodial activity 
and portray strong synergy when co-
administered with chloroquine. Also,    
C. senegalensis extracts have demonstrated 
significant antimalarial activity in a murine 
malaria model 
 
 
[18, 28, 59, 
60] 
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Phyllanthus spp 
(including P. 
muellerianus 
and Phyllanthus 
amarus) 
 
Phyllanthaceae Geraniin  
 
 
Significant prophylactic and 
chemotherapeutic antiplasmodial activity 
(dose-dependent) has been demonstrated by 
Phyllanthus amarus leaf extracts, 
comparable to chloroquine. This was 
assessed in P. Yoelli infected mice 
Saponins  Quillaja 
saponaria 
Quillajaceae Quillaja saponins  
including Quillaic 
acid 
Bark Extracts of Quillaja saponaria bark have 
shown potent antimalarial activity and are  in 
being examined as a potential preventive 
vaccine formulation, as a component of  
RTS,S, a subunit malaria vaccine candidate 
[61-63] 
Stilbenes 
/Lignins 
Carissa edulis 
 
Apocynaceae Nortrachelogenin  
 
Root 
Bark 
 
 
[64] 
Terpenoids Artemisia annua Asteraceae Cadinane 
sesquiterpenes 
including artemisinic 
acid, qinghao acid) 
and artemisinin 
Seed 
Leaves 
Semi synthetic artemisinin (and its 
derivatives) in combination is currently the 
favoured therapy against both drug-resistant 
and cerebral malaria-causing strains of 
Plasmodium falciparum, as it is active 
against both the sexual and asexual stages 
of the parasite cycle. Artemisinin is short-
acting with poor bioavailability  
[65-69] 
3. LIMITATIONS AND CHALLENGES OF FORMULATING 
PHYTOMEDICINES 
Although tremendous progress has been made in the research of phytomedicines, 
there is still much to be done towards progressing these to industrial scale 
formulations. It is noteworthy that the major pharmaceutical companies have 
demonstrated renewed interest use of phytomedicines as lead compound and sources 
of new drugs [70].  Although several phytomedicines form the basis of several new 
drugs, their delivery may pose a challenge due to several reasons. Some drawbacks 
encountered in the formulation of phytomedicines include: 
3.1 Poor aqueous solubility 
For medicines administered through the oral route to exert their effects, they should 
be in solution in order to cross the barriers to absorption, as this influences their 
bioavailability. Several phytomedicines are known to exhibit low systemic availability 
[71]. For instance, artemisinin (the first line treatment for malaria) has poor aqueous 
solubility, being incompletely absorbed following oral administration. This is due to its 
poor dissolution attributes in gastrointestinal fluids [72]. This has led to some difficulty 
in formulating dosage forms as a result of variable dissolution rates and erratic 
bioavailability [73]. It has been reported that absorption of artemisinin could be 
modified by other constituents of Artemesia annua as a clinical pharmacokinetic study 
showed artemisinin formulated as a herbal tea was absorbed rapidly and with shorter 
Tmax in comparison its administration as capsules [74]. There are several reports on 
the application of nanotechnology in improving solubility, bioavailability and bioactivity 
of phytochemicals [75-79]. Besides the use of nanotechnology, this low solubility could 
be overcome through the use of solid dispersion of water-soluble carriers, prodrugs, 
self-emulsifying systems, complexation with β-cyclodextrin etc. [80, 81]. 
3.2 Large molecular size 
Several constituents of phytomedicines show limited absorption. This may be as a 
result of the large molecular size of some of them, which hinders transport via passive 
diffusion. Some other have poor lipid solubility which serves as a barrier to crossing 
lipidic biological membranes, hence lower permeability [82]. These factors lead to low 
bioavailability of some phytomedicines. The formulation of phytosomes (achieved by 
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linking phytoconstituents to phosphatidylcholine) and herbosomes provide better 
absorbed dosage forms with better pharmacokinetic profiles [83, 84]. 
3.3 Standardization 
Standardisation of herbal medicines is a major limiting factor for their formulation and 
use as some are introduced into the market rigorous safety or toxicological evaluation, 
as their might be ineffective machinery to regulate manufacturing practices and quality 
standards in some countries [85]. The impact of environmental changes on the active 
ingredients influences the need to use pharmacological standardization to establish 
medicinal quality of the plants. In addition, insufficient scientific information about the 
acting pharmacological principles of the extracted phytocompounds (total extracts and 
isolated constituents) and the fact that the plants are not cultivated under controlled 
condition may partly be responsible for the failure to meet standardisation standards 
[86]. The differences in content, quantity and quality of some herbal products could be 
due to different extraction, processing and manufacturing methods utilised by 
manufacturers [87]. Also, there are reports on insufficient standardization and quality 
control of the herbal drugs used in clinical trials which may be due to different dosages 
of herbal medicines being used, improper randomization and use of insufficient 
number of patients, difficulty in establishing appropriate placebos (as a result 
organoleptic properties like taste and aroma) as well as variations in treatment 
durations [88]. All these factors make standardization difficult. 
3.4 Low yield 
Crude extracts of phytomedicines commonly contain several bioactives. The 
processes involved including appropriate plant identification, extraction processes, 
isolation of active constituents and fractionation process is time consuming. This, 
coupled with the low supply of the active ingredient supply eventually leads to low yield 
of the phytomedicines. This buttresses the need for advancement in combinatorial 
organic chemistry, discovery of semi-synthetic analogues as well as more sustainable 
extraction and purification techniques that may ensure higher yields [86]. A study 
demonstrated low yields of at least 0.16% for some lyophilized ethanol extract alkaloid 
fractionated from the antimalarial plant Himatanthus articulatus stem barks was 
fractionated by re-extraction under reflux yielding three fractions [89]. 
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3.5 Patient compliance and medication adherence 
It is well known that formulation and delivery methods could significantly influence the 
efficacy of a drug and inadvertently a phytomedicines. Many phytomedicines are 
presently available as teas, capsules, tablets, pressed juices, tinctures, solvent-
extracted preparations or combinations of these various product forms. These are 
traditional delivery systems and are met with less patient acceptability which may 
negatively affect adherence [82]. Poor patient compliance is also due to large doses 
and sometimes less effectiveness reported with some available formulations [82]. An 
approach reported to result in better patient compliance is the formulation of liquid or 
solid self-emulsifying drug delivery systems.  These are believed to lead to the 
formulations with enhanced solubility and bioavailability, better stability, more compact 
dosage forms, ease of handling/ portability; ultimately resulting in  better patient 
compliance [90]. In addition, concerns over compliance with plant-based medicines 
varies according to local beliefs and socio-cultural status, and is less reliant on the 
efficacy of the traditional medicine [86]. This attitude is likely to lead to a negative bias 
towards users of these phytomedicines as some patients may continue with such 
treatment although it may show insufficient efficacy as a result of personal and 
community beliefs. 
 
For these reasons, advanced drug delivery systems including nanotechnology-based 
systems provide several advantages that would be suitable for phytomedicines. These 
include, better targeting and more efficient delivery due to greater drug loading 
capacities, longer blood circulation times especially when linked to certain polymers, 
a decreased drug dose etc. 
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4. NANAOTECHNOLOGY INTERVENTIONS FOR OVERCOMING 
CHALLENGES OF PHYTOCHEMICAL ANTI-MALARIALS 
Current conventional drug treatment and delivery strategies for malaria are rife with 
several limitations. Table 2 illustrates the limitations of conventional drug delivery and 
how this can be overcome using nanotechnology based systems. The main concern 
with antimalarial drugs is their poor solubility, large dose, ability to damage healthy 
tissues, resulting in toxicity in addition to multidrug resistance by Plasmodium spp 
mediated by several factors including P-glycoprotein efflux transporters which have 
been resulted in poor uptake, low bioavailability and treatment failure. Advanced drug 
delivery systems and nanotechnology-based systems are steadily gaining increased 
interest in the management of malaria [91, 92]. Their better organ and tissue target 
ability, increased safety through decreased dosing requirements and reduced 
clearance makes them ideal for drug delivery, improving patients care. 
These systems would be grouped into three main categories and discussed as 
polymer-based, lipidic systems as well as miscellaneous systems. 
Table 2: Limitations of conventional delivery systems and the merits provided by nanotechnology-based delivery systems  
Attribute Conventional drug delivery systems Nanotechnology-based drug delivery systems References 
Size Larger size implies a smaller surface area, 
which can result in the delivery of drugs to the 
site of administration rather than the target site 
because they are less easily bio-distributed. 
Reduced intestinal uptake   and clearance by 
the mononuclear phagocyte system can occur 
due to their larger size  
The nanocarriers are generally of approximately 1-100nm in 
size. This size is similar to most biological molecules and 
structures so they can cross biological barriers, which 
increases bio-distribution. Increased surface area to volume 
ratio improves solubility and bioavailability. 
[93] 
Solubility and 
bioavailability 
Cannot always increase the drugs aqueous 
solubility so toxic excipients are sometimes 
utilised. 
The bioavailability is usually lower due to larger 
size and poor solubility. This can result in 
insufficient exposure and high inter-subject and 
intra-subject variability. For this reason, the 
intravenous route may be required 
Can provide hydrophilic and hydrophobic environments to 
enhance solubility of poorly soluble drugs 
This is more commonly associated with higher bio-availability 
due to small size and improved aqueous solubility. 
[94, 95] 
Pharmacokinetics When given orally can have lower bioavailability 
due to poor solubility of some APIs. They can 
also undergo first pass metabolism and rapid 
clearance from the body, further reducing their 
bioavailability. When given intravenously, the 
mononuclear phagocyte system can reduce 
half-life. 
Can improve the bioavailability of drugs by improving their 
solubility. Can also increase half-life by masking the drug 
molecule and reducing its immunogenicity.  
[96, 97] 
Targeting Do not normally have target-specific recognition 
moieties to target all cells. Therefore, higher 
concentrations of the drug are required to 
increase the drug concentration at the target 
site. This could result in healthy tissue damage 
and side effects. 
Active targeting using target-specific recognition moieties such 
as a small peptide, antibody or protein. This improves the 
drug’s efficacy and therapeutic index. Side effects and damage 
to healthy tissue is reduced so patient tolerability and 
compliance is improved. 
[98, 99] 
18 
 
 
Stimuli-responsive These are not normally formulated to respond 
to stimuli such as enzymes or pH. 
Could be responsive to pH, enzymes or other stimuli. Some 
nanotechnology-based systems are formulated so they release 
the drug molecules at certain pH, which increases drug 
concentration at the desired site. 
[100] 
Efficacy Comparable lower efficacy due to lower 
concentration of drug reaching the active site.  
Higher efficacy due to improved bioavailability, targeting, 
reduced degradation and clearance.  
[101, 102] 
4.1 Polymer-based delivery systems for antimalarial phytochemicals 
 
Dendrimers, polymeric micelles, polymeric nanoparticles and polymer-drug 
conjugates are some of the polymer-based nanotechnology systems commonly 
investigated and utilised for drug delivery. Several synthetic and natural polymers have 
been used in the formulation of nanotechnology systems including; polyesters, 
polyurethanes, polyanhydrides, polyoxolates, polydioxanones, chitosan, dextran, 
starch, heparin, gelatin etc [103-105]. In many instances, these polymers possess 
unique properties and are suitable for drug delivery, with the requirement that they 
should be biocompatible. This property of polymer biocompatibility often is associated 
with a biodegradable attribute of the polymer [103]. It has been shown that some of 
these polymers can increase the size of drug molecules, which helps to reduce renal 
clearance. They also have been reported to increase solubility and reduce 
immunogenicity by masking the drug molecule [106]. These polymeric nanocarriers 
synthesised from natural and synthetic monomer subunits, are one the most frequently 
investigated carrier system, where drugs can be conjugated covalently or incorporated 
via hydrophobic interactions [107, 108]. Antimalarial phytomedicines could either be 
conjugated onto the surface of these nanosystems or physically encapsulated within 
their structure, according to their preparation method. 
4.1.1 Dendrimers  
Dendrimers are composed of mono-dispersed, highly branched polymeric complexes 
(Figure 2a), which are produced by either convergent or divergent methods. As a result 
of their narrow polydispersity indices, uniform products are more easily manufactured 
[109]. Although dendrimers are of varying types, polypropyleneimine (PPI) and 
polyamidoamine (PAMAM) are commercially available and most commonly 
investigated [110, 111]. They are delivery systems for anionic, cationic, hydrophilic 
and hydrophobic drugs because full generation PAMAM dendrimers have terminal 
amino groups and half-generation dendrimers have carboxylate and ester groups 
[112].  PAMAM dendrimers have been investigated as a malaria vaccine delivery 
option. This was studied through an in silico computational model investigating and 
eight-branching unit which could be formed through combinations of epitopes obtained 
from the whole sequenced genome of P. falciparum [113]. PEG-lysine type dendritic 
peptide-based nanoparticulate carriers have been reported for sustained and 
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controlled delivery of artemether through intravenous route of administration. PEG-
amine was taken as core in the present system and various generations of dendritic 
nanoparticles were synthesized by fluorenyl methoxy carbonyl (FMOC)-based liquid 
phase peptide synthesis process. The systems were further conjugated with 
chondroitin sulphate [114]. In another study polymeric amphiphilic micellar system has 
been reported for solubilsation of artemether whereby methoxy polyethylene glycol 
(MPEG) 2000 and 5000 were used as hydrophilic terminal [115]. 
 
4.1.2 Polymeric micelles 
Polymeric micelles (Figure 2b) consist of amphiphilic copolymers which self-assemble, 
into spherical mono-layered structures in aqueous environment. Two discrete regions 
exist, a hydrophilic shell which encapsulates a hydrophobic core where poorly soluble 
drugs may be incorporated [116]. Poly(L-amino acid)s and poly(ester)s are common 
hydrophobic copolymers used for polymeric micelle formation. They are preferred for 
delivering hydrophobic drugs, improving their aqueous solubility and thus enhance oral 
bioavailability, so are well suited for several phytochemicals [117]. These polymeric 
micelles have also showed narrow polydispersity, enhanced stability and have small 
sizes of between 10-200nm [118], making them less likely to be  phagocytosed and 
cleared from the blood. Furthermore, reduced drug leakage is likely to occur with 
polymeric micelles compared to liposomes [119], making these carrier systems more 
stable as formulations. Polymeric micelles, however, have higher toxicity when 
compared to the lipid based formulations due to the attributes of some polymeric 
materials [120]. Phytomedicine-loaded polymeric nanomedicines use been reported 
[91, 121].  
Curcumin (a diarylheptanoid isolated form Curcuma longa) is well known for its antimalarial 
potency [122 123]. However, limiting factors such as its extremely low oral bioavailability 
hampers its application as therapeutic agent. Curcumin-loaded-4-Arm Poly(Ethylene 
Glycol)-Block-Poly(Anhydride-Esters) micelles prepared by a solid dispersion method 
have been reported with hydrodynamic diameter of 151.9 nm and the drug loading 
content of 7.0% and encapsulation efficiency 85.2%. Curcumin encapsulated within 4-
arm PEG-b-PAE micelles was amorphous and followed biphasic drug release pattern 
with rapid release at the initial stage and slow release later [124]. As polymeric micelles 
have been advocated as efficient drug delivery approach for multiple and combination 
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therapeutics it might prove useful for artemisinin-based combination, the first line 
malaria treatment [125]. 
4.1.3 Polymer-drug conjugates 
Polymer-drug conjugates are a widely used delivery system which has shown great 
potential in the delivery of therapeutic properties of proteins and small molecules. They 
offer significant benefits when compared to conventional drug delivery systems in 
terms of prolonged half-life, improved stability, enhanced aqueous solubility, reduced 
immune response and also specific targeting to tissues or cells [126]. Some of these 
properties could be improved following conjugation to water soluble polymers. 
Commonly utilised polymers include N-(2-hydroxypropyl) methacrylamide copolymer 
(HPMA), polyglutamic acid (PGA), polyvinylpyrrolidone (PVP) and poly (ethylene 
glycol) (PEG), while newer ones are routinely investigated and proposed [126].  
There are some studies exploiting polymer drug conjugates for malaria therapy. For 
instance a recent study by Kumar et al [127] demonstrated a delivery approach for 
radical cure of malaria utilising different polymer-drug conjugates with conventional 
antimalarials; primaquine and dihydroartemisinin in conjugation with either 2-propoxy 
substituted polyphosphazenes, 4-acetamidophenoxy substituted polyphosphazenes, 
4-formyl substituted polyphosphazenes and 4-aminoethylbenzoate substituted 
polyphosphazenes. The study concluded that the formulations showed promising 
antimalarial efficacy at lower doses in comparison to the standard drug combination, 
without any recrudescence over 5 weeks, suggesting its potent efficacy against 
resistant malaria [127].  
In another study, Yang et al investigated the use of biodegradable polymer-curcumin 
conjugate micelles with a view to enhance its drug loading and improve its delivery. In 
the study, a hydrophobic block containing poly (lactic acid) was utilised as the polymer 
with the use of tris (hydroxymethyl) aminomethane linker which was conjugated to 
multiple curcumin molecules while the hydrophilic block was methoxy-poly(ethylene 
glycol) (mPEG) [128]. This approach could be exploited in the delivery of curcumin as 
a nanophytomedicine.  
 
4.2 Lipid-based delivery systems 
Lipid-based carriers composed of natural and synthetic lipids have proved an attractive 
research area, with good biocompatibility, biodegradability and cell permeability. They 
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include liposomes, lipid nanoparticles and nanoemulsions. Their hydrophobicity 
enables them to cross the phospholipid bilayer of cells to increase permeability. 
However, the use of excipients to improve stability and kinetics can increase their toxic 
potential, which is still limited when compared to most polymeric based systems. 
Antimalarial drugs can be solubilised or encapsulated within the oil/lipids causing 
enhanced bioavailability. Both liposomes and solid lipid nanoparticles have been 
shown to cross the blood brain barrier and therefore could be useful drug strategy for 
cerebral malaria [129, 130]. Certain lipid liposomes have been used as adjuvants 
for vaccines for malaria, where they have shown the ability of simultaneously 
activating the major histocompatibility complex class I and II pathways and inducing 
antibody and cellular immune responses [31].   
4.2.1 Liposomes 
 
Liposomes are spherical amphiphilic phospholipids which self-assemble into bilayers 
encapsulating an aqueous core made up of a phospholipid bilayer (Figure 2c). This 
biphasic characteristic allows the encapsulation of both hydrophobic and hydrophillic 
drugs. They have been most successful in gaining FDA (the Food and Drug 
Administration) approval, after the first liposome formulation Doxil® (Doxorubicin) 
have been reported to improve efficacy and minimise drug toxicity. Besides the ability 
to be formulated for controlled release, they have relatively longer circulation time, 
permitting sufficient accumulation at the parasitic site. PEGylation can increase 
bioavailability of liposomal drugs as opsonisation by macrophages is prevented, 
reducing the clearance rate [132]. PEG is a water soluble, generally non-toxic and 
non-immunogenic surface modifier, which is used to prolong circulation time because 
PEG chains are hydrated and flexible so they interact less with plasma proteins and 
cells surfaces. Liposomal targeting could also be enhanced by attaching ligands, such 
as antibodies on the surface which are specific to a receptor on the target cell. 
Generally, liposomes have the advantage of providing good entrapment of 
hydrophobic compounds and easy preparation. Stability is sometimes a concern which 
may be addressed by lyophilisation, although this process can rupture the lamellar 
phase resulting in leakage of the encapsulated drug. A potential drawback of 
conjugated liposomes is their relatively large size, which causes them to usually be 
recognised as foreign and removed via the mononuclear phagocytic system [133].  
23 
 
Artemisinin and its derivatives (including dihydroartemisnin) form WHOs first line 
treatment of malaria, though they are being now investigated for their anticancer 
properties. A study investigated liposome as formulation strategy towards obtaining 
effective delivery of dihydroartemisinin (DHA) Because of its poor water solubility, low 
bioavailability and low half-life (34–90 min), there is urgent need for development of 
improvised formulation of DHA. The formulation properties were assessed in terms of 
size and morphology, zeta-potential, polydispersity index, physical and chemical 
stabilities and encapsulation efficiency [134]. Curcuminoids are polyphenols derived 
from the root of Curcuma longa, which have shown potential in managing malaria. 
Aditya et al. explored the potential of liposomes for the intravenous delivery of 
curcuminoids using a mouse model, where curcuminoids-loaded liposomes alone and 
in combination with α/β arteether were evaluated in Plasmodium berghei infected 
mice. The study concluded that the curcuminoids-loaded liposomes showed promising 
and improved antimalarial activity [135].  
In another study four liposomal formulations were investigated viz. Artemisinin-loaded 
conventional liposomes (A-CL), artemisinin-curcumin-loaded conventional liposomes 
(AC-CL), artemisinin loaded PEGylated liposomes (A-PL) and artemisinin-curcumin-
loaded PEGylated liposomes (AC-PL)  prepared using film hydration method. The 
artemisinin-loaded PEGylated liposomes showed strongest antiplasmodial activity 
when tested in P. berghei NK-65- infected mice. All the liposomal treatments extended 
the period of survival of the mice until 30 days post-inoculation as compared to 
negative control group which died 12 days post inoculation, showing 40% increased 
parasitaemia levels. During the course of treatment, reduction in parasitaemia was 
faster in mice infected with P. berghei and treated with AC-PL, which reduced the 
parasitaemia to about 60% of the initial value after only 3 days. In all liposomal 
treatments, parasitaemia was reduced more than 93% of the initial value starting from 
day 5. The infection was almost totally reverted in mice treated with A-CL after 7 days 
and with AC-CL, A-PL and AC-PL after 5 days thus proving the potential of liposomes 
in delivery of antimalarial phytochemicals (136).  
4.2.2 Lipid nanoparticles 
Solid lipid nanoparticles (SLNs), illustrated in Figure 2d are colloidal carriers which are 
formulated using lipids that are solid at room temperature. They are easily prepared 
via high pressure homogenization, ultrasonication and microemulsion template 
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techniques, allowing for high scale production. Hydrophobic compounds are easily 
encapsulated into the solid lipid core, leading to an increased stability, reduced 
degradation, sustained and prolonged release. Formulating drugs as SLNs has also 
been reported to result in decreased toxicity and enhanced target specificity of drugs. 
These SLNs are usually formulated with solid lipids, surfactants and water, with the 
lipids usually of relatively high melting points [137, 138]. Similar to liposomes, they are 
well suited for the delivery of hydrophobic drugs, but are reported to have improved 
stability, especially when coated with polymers like polyethylene glycol (PEG) [137]. 
PEG, a versatile surface agent capable of increasing aqueous and lipid solubility, also 
confers good permeability across biological membranes [138]. However, some 
formulations with SLNs have also shown enhanced clearance by the 
reticuloendothelium system [139, 140]. Gupta et al have investigated delivery of 
quinine to the brain as transferrin-conjugated solid lipid nanoparticles. Quinine is 
widely used in the management of cerebral malaria and this effect was investigated in 
albino rats, where it was concluded that there was an enhanced uptake in brain tissue 
when the transferrin conjugated SLN was compared with unconjugated SLNs. In 
addition, plasma drug concentrations observed were higher than following SLN 
administration in comparison with the conventional intravenous dose [141].  
Curcumin, despite its great potential to be developed as a drug, is limited by its low 
aqueous solubility, poor stability and low bioavailability following oral administration 
[142]. Curcumin loaded lipid nanocarrier have been reported to be very effective 
approach for enhancing the oral absorption of poorly water-soluble curcumin and have 
great potential for future clinical application [143,144. Memvanga et al. formulated a 
lipid-based drug delivery system with curcumin which was reported to have a high drug 
loading capacity, high aqueous solubility and enhanced cell permeability. Its 
antimalarial efficacy was enhanced as well as a significant delay in recrudescence in 
Plasmodium berghei-infected mice was observed when the curcumin-lipid based drug 
delivery system was combined with a sub-therapeutic dose of β-arteether [145]. This 
is suggestive of a promising approach for the treatment of malaria, where an 
artemisinin-based combination therapy produces better therapeutic outcomes 
[146,147].  
Nayak et al demonstrated the use of lipid nanoparticles for the delivery of curcuminoids 
for parenteral administration. For the production of nanoparticles, trimyristin, tristerin 
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and glyceryl monostearate were selected as solid lipids and medium chain triglyceride 
(MCT) as liquid lipid. In vivo pharmacodynamic activity revealed 2-fold increase in 
antimalarial activity of curcuminoids entrapped in lipid nanoparticles when compared 
to free curcuminoids [148].   
Nanostructured lipid carriers (NLCs) are lipid nanocarriers formulated using 
biocompatible solid lipid and liquid lipids (oil). The aqueous nature of NLC, their 
nanostructure and the biocompatibility of the excipients enables intravenous delivery 
of the therapeutic agents using this nanocarrier [149]. Also NLCs provide sustained 
delivery thus maintaining drug levels for prolonged period of time which is helpful in 
combating recrudescence commonly associated with antimalarial drugs. Joshi et al, 
have reported nanostructured lipid carriers (NLC) for the intravenous delivery of 
artemether (ARM) employing microemulsion template technique (63±28 nm), 
encapsulation efficiency (30±2%) and sustained release up to 24h. ARM-NLC had 
lower haemolytic potential (∼13%) as compared to all the formulation components 
when studied individually. In vivo studies clearly demonstrated that ARM-NLC  was 
significantly more effective as compared to the marketed formulation (Larither®) 
indicating the advantage of NLC. ARM-NLC showed quick onset of action (∼95% 
antimalarial activity) as compared to marketed injection  (∼45% antimalarial activity) 
and demonstrated antimalarial activity for a longer duration indicating that ARM-NLC 
may be long circulating in-vivo and that entrapped ARM may be released in a 
sustained manner. ARM-NLC showed significantly higher survival rate after 31 days 
as compared to marketed formulation, which showed no survival proving the 
advantage of the NLC system over the marketed oily intramuscular formulation 
(Larither®) [150]. 
Chinaeke et al examined the in vitro-in vivo correlation of wax-soybean oil-based 
artesunate-loaded lipospheres. It was revealed that the formulated lipospheres had 
maximum encapsulation efficiency of 80%, with a bioavailability enhancement factor 
of 2.108 when compared with tablets [151]. These studies show the potential of 
improved efficacy if phytochemicals are formulated as nanolipid systems.  
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4.2.3 Nanoemulsion 
Lipid nanosized emulsions or nanoemulsions (NE) are dispersions of nanosized oil 
droplets which are immiscible in the stationary continuous phase, synthesised from 
bio-acceptable components, capable of integrating hydrophobic drug in the nano-
range, yielding greater surface area [152]. 
Arteether nanoemulsion (ARTE-NE) has been reported as oral delivery system for 
arteether (ARTE) for improving its solubility and bioavailability. The pharmacokinetic 
study showed significantly enhanced bioavailability of ARTE in ARTE-NE. The ARTE-
NE showed significantly high antimalarial efficacy and survival rate of mice giving 80% 
cure rate at 12.5 mg/kg for 5 days in comparison to 30% cure rate of ARTE in 
groundnut oil at the same daily dose and it was also comparable to the 100% cure rate 
at 12.5 mg/kg for 5 days for ART given intramuscularly [153].  
 
Microemulsion preconcentrate for artemether (~183 nm, PDI 0.498) exhibited 2.6-fold 
higher antimalarial activity than the marketed formulation Larither®. Nanosize of the 
microemulsion, instantaneous dissolution of the drug, quick absorption, enhancement 
in bioavailability, protection of from acidic microenvironment of stomach and 
antimalarial effect of the excipients have been listed as possible attributes responsible 
for higher activity [154].  
 
4.3 Miscellaneous nanotechnology-based drug delivery systems 
Some nanotechnology-based drug delivery systems that do not fit into the broad 
categories of polymer or lipid-based systems, and would be discussed as 
miscellaneous systems. These include metallic nanoparticles, carbon nanotubes, 
nanosuspensions etc. 
4.3.1 Carbon nanotubes 
Carbon nanotubes (CNT) are drug delivery systems made of graphite and constructed 
in cylindrical tubes, which are able of adsorbing or linking to several therapeutic and 
diagnostic agents [155-157] (Figure 2e). Single-walled CNT and multi-walled CNT are 
the main types, which are imaginatively produced by rolling up a single layer of 
graphene sheet or by rolling up many layers to form concentric cylinders [158, 159]. 
They have good attributes, as a result of their nanosize and minute mass, strong 
mechanical potency, coupled with high electrical and thermal conductivity [160]. 
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Despite their potential for medical and pharmaceutical applications, many CNT are 
insoluble in all solvents, generating health concerns related to their toxicity [161, 162].  
They are considered as an immunization strategy for antigen delivery against 
infectious diseases and show promise for future malaria vaccine application [163]. It 
is thought that if antigens are encapsulated within CNTs, they could be more protected 
from external factors and maintains their correct conformation, further enhancing their 
immunization potential [164, 165]. 
A study reported the use of an immunosensor using antibody raised against HRP II 
for detecting Plasmodium falciparum. Here, disposable screen-printed electrodes 
were modified with multiwall carbon nanotubes and gold nanoparticles which 
demonstrated significantly high levels of detection, explaining its use as a potential 
biomarker for fast and reliable malaria detection [166]. The potential of CNTs in the 
delivery of artemisinin and its derivatives for malaria have also been investigated [167]. 
There is paucity of information on the use of CNT as a drug delivery method for malaria 
phytomedicines, although they have demonstrated some promise. 
4.3.2 Metallic nanoparticles 
Metal and magnetic nanoparticles (including those of aluminium, silicon, iron, 
cadmium, selenium, gold, indium, calcium and silver) have gained significant interest 
in recent years [168]. Their chemical functional groups are usually modified, allowing 
their conjugation with therapeutic proteins, ligands and organic/inorganic molecules 
for several applications. They find application in diagnostic imaging, as means for 
targeted drug delivery and vehicles for gene therapy [169, 170]. Auranofin (AF) is an 
effective gold compound used for the treatment of malaria. The combination of 
artemisinin and AF has showed synergistic antimalarial effects [171] Streptomyces 
spp LK-3 (JF710608) mediated gold nanoparticles (Au-N-LK3) have been prepared by  
inoculation of  Streptomyces spp LK-3 (JF71060)  into 100 ml of broth (50% sea water) 
and incubated in rotary shaker incubator at 28°C for 7 days. Chloroauric acid aqueous 
solution was added mixture was kept in shaker at 28°C at 120 rpm for 24 hrs to obtain 
gold nanoparticles (5-50 nm). Au-N-LK3 treatment in Plasmodium berghei ANKA 
(PbA) infected mice delayed the parasitemia rise (~6%) compared to PbA infection on 
8 days post infection. Survivability of mice increased to ~85% in Au-N-LK3 treated 
mice in contrast to in PbA (~50%) infected mice, 8 day post infection with respect to 
control. No histological changes were observed in in spleen and liver tissue and 
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confirmed up-regulation of TGF-β and down-regulation of TNF-α in tissue and serum 
levels in Au-N-LK3 treated mice [172]Al-Deen et al have reported the use of 
superparamagnetic iron oxide nanoparticles to facilitate delivery of a malaria DNA 
vaccine into eukaryotic cells, where the application of an external magnetic field 
significantly enhanced transfection efficiency [173]. 
4.3.3 Nanosuspensions 
Nanosuspensions involve a nanosized drug being suspended in either an aqueous or 
oily medium. They are advantageous over some other drug delivery systems as the 
drug itself is nanosized and suspended, rather than being encapsulated/conjugated 
within a carrier, thus ensuring 100% drug loading and encapsulation efficiency. In 
comparison, nanosuspensions are relatively simple systems composed of drug 
nanoparticles and surfactants required for dispersion, formulated for a range of routes. 
Being crystalline nanosized drug particles, their small size increases their surface 
area, allowing for greater dissolution rate and improves the bioavailability of 
hydrophobic drugs [174].This approach has been reported for dihydroartemisinin 
(DHF) whereby DHF nanosuspension with mean particle size of 80-220 nm showed 
higher activity on P. falciparum K1 strain [175]. In another study, nanotized curcumin 
was reported to be non-toxic, with a narrow poly dispersity index and improved 
aqueous dispersibility. The formulation further demonstrated very significant growth 
inhibition of Plasmodium falciparum and Plasmodium berghei-infected mice [176]. 
These systems show great potential for the delivery of insoluble malaria 
nanophytomedicines.  
4.3.4  Pheroids 
Pheroid technology is a patented colloidal delivery system consisting of a dispersed 
phase of plant based essential fatty acid in a nitrous oxide saturated continuous water 
phase. It consists of a lipid bilayer that is dynamic and constantly changing, with high 
stability and ability to entrap both hydrophilic and lipophilic drugs. The structure and 
size of Pheroid system can be manipulated for various applications [177].  Pheroid 
vesicle formulations of Artemisone - novel artemisinin derivative with good antimalarial 
activity but poor and erratic absorption and low bioavailability, have been prepared by 
heating and mixing vitamin F ethyl ester, Cremaphor® EL and tocopherol along with  
PEG 400 and BHA to form the oil phase. The drug was added to oil-phase at room 
temperature and agitated to dissolve drug particles. The nitrous oxide water was then 
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added to the oil-phase (1:9 v/v). The mixture was homogenised at 8000 rpm for 1 min. 
Pharmacokinetic behaviour of the developed formulation showed that the Tmax of 
artemisone, when incorporated in the Pheroid vesicle formulation, was delayed by a 
time-factor of 4 in comparison to that of the reference formulation. The Cmax for 
reference formulation produced a Cmax of 809.5 ng/ml while the Pheroid vesicle 
formulation gave a Cmax of 1550.0 ng/ml.  The reference formulation had a t1/2 of 
approximately 20 min while the Pheroid vesicle formulation extended the t1/2 to more 
than 60 min. The Pheroid formulation was absorbed 4.57 times better than the 
reference formulation  [178]. 
 
5. Conclusions and Future Perspectives 
This review article highlights some nanoparticulate systems which are being modified 
for their potential applications in the treatment of malaria. Nanotechnology-based 
systems are developing to produce feasible, practical formulations, more thought to 
emerge in the next few years, with improved pharmacokinetic profiles, lower 
incidences of recrudescence and improved bioavailability. Despite their demonstrated 
successes; numerous challenges remain before some of these nanophytomedicines 
systems especially regarding standardisation, safety, stability, costs and drug loading. 
For instance, with respect to their toxicity, some of their components could cause 
immunotoxicity when they act as antigens. In addition, as a result of the relatively low 
encapsulation efficiency and loading capacity of some of these drug delivery systems, 
higher amounts of excipients used in their formulation could lead to other toxicities. 
Future research would need to address these issues and assess performance in 
humans (as most studies conducted in cell lines and animal in vivo models may not 
translate to humans). This presents significant challenges in ensuring that these 
become clinically viable therapies. The design and testing of novel methods of 
controlling the interaction of nanomaterials with the body are some of the current 
barriers to translating these technologies to therapies. Furthermore, it seems 
reversible PEGylation and versatile excipients such as d-α-tocopheryl polyethylene 
glycol 1000 succinate hold much promise in establishing nanophytomedicines as a 
reality. Although the development of phytomedicines-based nanotechnology drug 
delivery systems is still emerging, it shows a promising future. 
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Figure legends 
Figure 1:  Chemical structures of (a) polyphenols (b) flavone (c) flavonol (d) 
flavanone (e) flavanonol (f) gallic acid (g) dibenzylbutane skeleton, the 
base structure for several lignans (h) base structure of stilbenes (i) 
anthraquinones (j) coumarins (k) cyanogenic glycosides (l) steroid 
structure base for saponin glycosides (m) steviol (n) isoprene structure, 
the base for terpenoids 
Figure 2:     Illustration of nanotechnology-based delivery systems (a) 
poly(amido)amine (PAMAM) dendrimer (b) polymeric micelle (c) 
liposomes (d) solid lipid nanoparticle (e) carbon nanotube 
 
Table legends 
Table 1:  Phytochemicals reported for their antimalarial effect 
Table 2:  Limitations of conventional delivery systems and the merits provided by 
nanotechnology-based delivery systems   
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Figure 1:  Chemical structures of (a) polyphenols (b) flavone (c) flavonol (d) 
flavanone (e) flavanonol (f) gallic acid (g) dibenzylbutane skeleton, 
the base structure for several lignans (h) base structure of stilbenes 
(i) anthraquinones (j) coumarins (k) cyanogenic glycosides (l) 
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steroid structure base for saponin glycosides (m) steviol (n) 
isoprene structure, the base for terpenoids 
 
 
 
 
Figure 2:     Illustration of nanotechnology-based delivery systems (a) 
poly(amido)amine (PAMAM) dendrimer (b) polymeric micelle (c) 
liposomes (d) solid lipid nanoparticle (e) carbon nanotube 
 
